Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.

Serelaxin treatment elicited a selective, highly significant, and clinically relevant increase in total RBF that was associated with a substantial reduction in RVR but only a small increase in superior aortic flow, as a surrogate of increased CO ( Fig 7 ).

also in 132,142 other papers